Frontiers in Psychology
March 4, 2022
Agnieszka D. Sekula, Luke A. Downey, Prashanth Puspanathan
27 citations
Psychotherapy with the use of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxymethamphetamine (MDMA), has demonstrated promise in treatment of post-traumatic stress disorder (PTSD), anxiety, addiction, and treatment-resistant depression. Psychedelic-assisted psychotherapy (PP) represents a unique psychopharmacological model that...
medRxiv
March 2, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
preprint
Abstract Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy...
Journal of Psychopharmacology
March 1, 2022
Max Wolff, Lea J. Mertens, Marie Walter et al.
57 citations
Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...
Journal of Psychoactive Drugs
February 28, 2022
Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al.
47 citations
There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the "Psychedelic Renaissance." This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain...
Journal of Xenobiotics
February 7, 2022
Maurizio Coppola, Francesco Bevione, Raffaella Mondola
29 citations
Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...
Cureus
February 5, 2022
Shawn Ziff, Benjamin Stern, Gregory D. Lewis et al.
32 citations
Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A...
Journal of Psychopharmacology
February 1, 2022
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al.
419 citations
Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods: This...
International Journal of Science and Research Methodology
January 31, 2022
Reace L. Hammel, Berry J. Gulliver, Shelby N. Sukich et al.
1 citation
Background: The impact of psychedelic treatment on patients with posttraumatic stress disorder (PTSD) has become more intriguing to the psychiatric field. Because of the stigma surrounding illicit drug use, the scientific communities were unable to conduct thorough studies regarding the effects of psychedelics on the brain. These drugs could help many people with mental illnesses that have not...
Frontiers in Pharmacology
January 27, 2022
Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al.
44 citations
Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT 2A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism...
Family Practice
January 24, 2022
James Bailey Sanford
Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a...